Janssen Pharmaceuticals, Inc.

Janssen Pharmaceutica Nv

Vanina Popova

Wayne C Drevets

Srihari Gopal

Adam Savitz

Chakradhar Lagishetty

Rama Melkote

Iva Kezic

Darrel Pemberton

Mark Schmidt

Philippe Fernandes

Jaskaran Singh

Ella Daly

Margaret Fedgchin

Nicolaas Martha Felix Goyvaerts

Geert Van Der Avoort

David Wood Hough

Katarina Jokicevic

Laura Martinez Marcos

Tom Huybrechts

Tatiana Marcozzi

Mahesh N Samtani

Matthieu Ravelingien

The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.

Compositions and methods for the treatment of depression

The present disclosure relates to compositions, including oral compositions in the form of tablets, comprising aticaprant and methods of using the same.

Compositions comprising aticaprant

The disclosure provides crystalline and amorphous forms of aticaprant. Also provided by the disclosure are pharmaceutical compositions comprising the amorphous or crystalline forms, methods of treating major depressive disorder using the amorphous or crystalline forms of aticaprant, amorphous or crystalline forms of aticaprant for use in the treatment of major depressive disorder in a human patient having anhedonia, uses of the amorphous or crystalline forms of aticaprant in the manufacture of a medicament for the treatment of major depressive disorder, and packages or pharmaceutical products comprising (i) amorphous or crystalline forms of aticaprant and (ii) instructions for treating major depressive disorder. In some aspects, the human patient treated as described herein has anhedonia.

Forms of aticaprant

The present invention provides methods for treating depression in a patient, comprising administering to the patient in need of the treatment a therapeutically effective amount of esketamine. In some embodiments, the depression is major depressive disorder or treatment resistant depression. In other embodiments, the therapeutically effective amount is clinically proven safe and/or effective. Also provided are methods to mitigate the risk or misuse or abuse of esketamine, instructions for use of the esketamine product, and methods for selling a drug product containing esketamine.

Esketamine for the treatment of depression

Growing community of inventors

Nijlen, Belgium

Vanina Popova